de Graaf G, Engelen J J M, Gijsbers A C J, Hochstenbach R, Hoffer M J V, Kooper A J A, Sikkema-Raddatz B, Srebniak M I, van der Kevie-Kersemaekers A M F, van Zutven L J C M, Voorhoeve E
Dutch Down Syndrome Foundation, Meppel, The Netherlands.
Department of Clinical Genetics, Research Institute Growth and Development (GROW), Maastricht University Medical Center, Maastricht, The Netherlands.
J Intellect Disabil Res. 2017 May;61(5):461-470. doi: 10.1111/jir.12371. Epub 2017 Mar 5.
In Western countries, increasing maternal age has led to more pregnancies with a child with Down syndrome (DS). However, prenatal screening programs, diagnostic testing and termination of pregnancy influence the actual DS live birth (LB) prevalence as well. The aim of this study is to examine these factors in the Netherlands for the period 1991-2015. In our study, we establish a baseline for DS LB prevalence before non-invasive prenatal testing will be made available to all pregnant women in the Netherlands in 2017.
Full nationwide data from the Dutch cytogenetic laboratories were used to evaluate the actual DS LB prevalence. In addition, nonselective DS prevalence, which is the DS LB prevalence that would be expected in absence of termination of pregnancies, was estimated on the basis of maternal age distribution in the general population.
Because of an increase in maternal age, nonselective DS prevalence increased from around 15.6 [95% confidence interval (CI) 13.9-17.4] per 10 000 LBs in 1991 (311 children in total) to around 22.6 (95% CI 20.3-24.9) per 10 000 in 2015 (385), the increase levelling off in recent years. Actual LB prevalence rose from around 11.6 (95% CI 10.9-12.2) per 10 000 in 1991 (230 children) to an estimated peak of 15.9 (95% CI 15.6-16.2) per 10 000 in 2002 (322), gradually decreasing since to 11.1 (95% CI 10.8-11.5) per 10 000 in 2015 (190). Reduction of DS LBs resulting from elective terminations had been fairly constant between 1995 and 2002 at around 28% and rose afterwards from 35% in 2003 to around 50% in 2015.
In spite of expansion of antenatal screening in the Netherlands in the 1990s and early 2000s, actual DS LB prevalence increased during this period. However, after 2002, this trend reversed, probably because of informing all pregnant women about prenatal testing since 2004 and the implementation of a national screening program in 2007.
在西方国家,孕产妇年龄的增加导致更多怀有唐氏综合征(DS)患儿的妊娠。然而,产前筛查项目、诊断检测和终止妊娠也会影响实际的DS活产(LB)患病率。本研究的目的是调查1991 - 2015年期间荷兰的这些因素。在我们的研究中,我们在2017年荷兰所有孕妇都可进行无创产前检测之前,建立了DS LB患病率的基线。
使用荷兰细胞遗传学实验室的全国完整数据来评估实际的DS LB患病率。此外,根据一般人群中的孕产妇年龄分布,估计了非选择性DS患病率,即假设不终止妊娠时预期的DS LB患病率。
由于孕产妇年龄增加,非选择性DS患病率从1991年每10000例活产中约15.6例[95%置信区间(CI)13.9 - 17.4](共311例患儿)增加到2015年每10000例中约22.6例(95% CI 20.3 - 24.9)(385例),近年来增长趋于平稳。实际LB患病率从1991年每10000例中约11.6例(95% CI 10.9 - 12.2)(230例患儿)上升到2002年估计的峰值每10000例中15.9例(95% CI 15.6 - 16.2)(322例),此后逐渐下降至2015年每10000例中11.1例(95% CI 10.8 - 11.5)(190例)。1995年至2002年期间,选择性终止妊娠导致的DS活产减少率相当稳定,约为28%,之后从2003年的35%上升至2015年的约50%。
尽管20世纪90年代和21世纪初荷兰的产前筛查有所扩大,但在此期间实际的DS LB患病率仍有所上升。然而在2002年之后,这一趋势发生逆转,可能是因为自2004年起向所有孕妇告知了产前检测情况以及2007年实施了国家筛查项目。